Figure 2.

Patient disposition during the core trial and extension phase.

FP/FORM, fluticasone propionate/formoterol fumarate; FP/SAL, fluticasone propionate/salmeterol xinafoate; OLE, open-label extension phase; ^*patient withdrew by choice; ^$two patients withdrew by choice; one patient withdrew for administrative reasons.